Table 3: Demographic and clinical data in 65 patients with CV event and 279 patients without CV events.

Characteristics With CV events (n. 65) Without CV events (n. 279) p
Demographics F/M 43/22 224/55 0.02
Mean age at onset, years (SD) 54.4 (12.3) 45.7 (15.6) < 0.0001a
Mean age at baseline, years (SD) 60.8 (10) 54.3 (11.9) < 0.0001a
Mean drug exposure duration, years (SD) 14.3 (6.9) 18.4 (8.8) 0.04a
Mean RA duration at last observation, years (SD) 18.7 (7.1) 18.4 (8.8) 0.84a
Anti-TNF alfa exposure, n. (%) 21/65 (32) 65/214 (30.3) 0.76
Comorbidities Arterial hypertension (%) 17/37 (45.9) 41/156 (26.2) 0.032
Smoking habits (%) 10/35 (28.5) 37/156 (23.7) 0.56
Dyslipidemia (%) 24/65 (36.9) 17/153 (11.1) < 0.0001
Familiar CV disease (%) 45/65 (69.2) 113/279 (40.5) < 0.0001
Diabetes (%) 10/43 (23.2) 7/156 (4.4) < 0.0001
CAD (%) 4/38 (10.5) 4/279 (1.4) 0.005
Mean n. Framingham risk factors at the CV event (SD) < 0.0001b 5.98 (7.2) < 0.0001b
CV-related drugs B blockers (%) 29 (44.6) 44/278 (15.8) < 0.0001
Ace inhibitors (%) 29 (44.6) 42/278 (15.1) < 0.0001
Diuretics (%) 25 (38.4) 48/278 (17.2) < 0.0001
Anti-platelets (%) 39 (60) 53/279 (18.9) < 0.0001
Oral anti-coagulants (%) 12 (18.4) 7/279 (2.5) < 0.0001
Statins (%) 18 (27.6) 25/279 (8.9) < 0.0001

a = Unpaired t test; b = Mann-Whitney test.